Converting to IDegLira is efficacious regardless of pre-trial insulin dose in patients with type 2 diabetes uncontrolled on insulin glargine U100

被引：0
|
作者：
Meneghini, L. F. [1 ]
Jaeckel, E. [2 ]
Leiter, L. A. [3 ]
Lingvay, I. [1 ]
Harvey, J. N. [4 ]
Begtrup, K. [5 ]
Chandarana, K. [5 ]
Vilsboll, T. [6 ,7 ]
机构：
[1] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA
[2] Hannover Med Sch, Hannover, Germany
[3] Univ Toronto, Toronto, ON, Canada
[4] Bangor Univ, Wrexham, Wales
[5] Novo Nordisk AS, Soborg, Denmark
[6] Univ Copenhagen, Steno Diabet Ctr Copenhagen, Gentofte, Denmark
[7] Gentofte Univ Hosp, Ctr Diabet Res, Copenhagen, Denmark
来源：
DIABETOLOGIA | 2017年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
671
引用
收藏
页码：S306 / S306
页数：1
相关论文
共 50 条
  • [31] Lower rate of hypoglycaemia with IDegLira vs insulin glargine regardless of dosing time or hypoglycaemia definition in patients with Type 2 diabetes
    Norwood, P.
    Chen, R.
    Jaeckel, E.
    Lingvay, I.
    Jarlov, H.
    Lehmann, L.
    Heller, S.
    DIABETIC MEDICINE, 2017, 34 : 142 - 143
  • [32] Lower rate of hypoglycaemia with IDegLira vs insulin glargine regardless of dosing time or hypoglycaemia definition in patients with type 2 diabetes
    Norwood, P.
    Chen, R.
    Jaeckel, E.
    Lingvay, I.
    Jarlov, H.
    Lehmann, L.
    Heller, S.
    DIABETOLOGIA, 2016, 59 : S429 - S430
  • [33] Comparison of the Impact of Insulin Degludec U100 and Insulin Glargine U300 on Glycemic Variability and Oxidative Stress in Insulin-Naive Patients With Type 2 Diabetes Mellitus: Pilot Study for a Randomized Trial
    Cindro, Pavle Vrebalov
    Krnic, Mladen
    Modun, Darko
    Vukovic, Jonatan
    Kurir, Tina Ticinovic
    Kardum, Goran
    Rusic, Doris
    Perisin, Ana Seselja
    Bukic, Josipa
    JMIR FORMATIVE RESEARCH, 2022, 6 (07)
  • [34] A short-term cost-utility analysis of insulin degludec versus insulin glargine U100 in patients with type 1 or type 2 diabetes in Denmark
    Pollock, R. F.
    Tikkanen, C. K.
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (03) : 213 - 220
  • [35] IDEGLIRA IMPROVES HEALTH UTILITY COMPARED WITH INSULIN GLARGINE IN PATIENTS WITH TYPE 2 DIABETES
    Freemantle, N.
    Lingvay, I
    Kongso, J. H.
    Abrahamsen, T. J.
    Bjorner, J. B.
    VALUE IN HEALTH, 2015, 18 (07) : A614 - A614
  • [36] Cost-Effectiveness of Insulin Degludec vs. Insulin Glargine U100 in Type 1 and Type 2 Diabetes Mellitus in a UK Setting
    Evans, Marc
    Mehta, Roopa
    Gundgaard, Jens
    Chubb, Barrie
    DIABETES THERAPY, 2018, 9 (05) : 1919 - 1930
  • [37] Erratum to: Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA
    Barnaby Hunt
    Michelle Mocarski
    William J. Valentine
    Jakob Langer
    Advances in Therapy, 2017, 34 : 1500 - 1501
  • [38] CGM Parameters for once a week Administration of Insulin icodec versus daily Administration of Insulin glargine U100 in insulin-naive Female Patients with Type 2 Diabetes
    Mader, Julia K.
    Lingvay, Ildiko
    Beck, Bang R.
    Koefoe, Mette M.
    Pettus, Jeremy
    Wagner, Lily
    Mathieu, Chantal
    WIENER KLINISCHE WOCHENSCHRIFT, 2021, 133 (SUPPL 6) : 200 - 201
  • [39] Cost-Effectiveness of Insulin Degludec vs. Insulin Glargine U100 in Type 1 and Type 2 Diabetes Mellitus in a UK Setting
    Marc Evans
    Roopa Mehta
    Jens Gundgaard
    Barrie Chubb
    Diabetes Therapy, 2018, 9 : 1919 - 1930
  • [40] Traveling Across Time Zones With Type 1 Diabetes: A Pilot Study Comparing Insulin Degludec With Insulin Glargine U100
    Bevier, Wendy C.
    Castorino, Kristin N.
    Axelrod, Ceara
    Haroush, Gal
    Farfan, Christian C.
    Shelton, Nina
    Nelson, Kristen
    Spink, Lisa A.
    Liu, Hanqing
    Kerr, David
    DIABETES CARE, 2022, 45 (01) : 67 - 73
12345